Calendrier des promotions Rezolute, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Rezolute, Inc.
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. plus de détailsParamètres de base
IPO date
2014-05-01
ISIN
US76200L3096
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 0 | 0 |
| P/BV | 1.65 | 8 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -53.39 | 0 |
| ROE | -57.73 | 0 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | -0.0326 | 10 |
| Debt/Ratio | 0.0168 | 10 |
| Debt/Equity | 0.097 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 0 | 0 |
| Rentabilité Ebitda, % | 237.06 | 10 |
| Rentabilité EPS, % | -61.99 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 3.83 $ | 0 $ | 0 $ | 4.44 % | 0 % | 0 % |
| common.calendar.number_days.7d | 4.01 $ | 0 $ | 0 $ | -0.25 % | 0 % | 0 % |
| common.calendar.number_days.30d | 3.76 $ | 3.49 $ | 4.01 $ | 6.38 % | 0 % | 0 % |
| common.calendar.number_days.90d | 4.46 $ | 2.47 $ | 4.12 $ | -10.31 % | 0 % | 0 % |
| common.calendar.number_days.180d | 4.99 $ | 2.47 $ | 5.57 $ | -19.84 % | 0 % | 0 % |
| common.calendar.number_days.1y | 3.69 $ | 2.47 $ | 5.96 $ | 8.4 % | 0 % | 0 % |
| common.calendar.number_days.3y | 3.08 $ | 0.738 $ | 5.96 $ | 29.87 % | 0 % | 0 % |
| common.calendar.number_days.5y | 0.0868 $ | 0.093 $ | 24.05 $ | 4508.29 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0 $ | 0.062 $ | 24.05 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 4.08 $ | 2.47 $ | 5.57 $ | -1.96 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Nevan Charles Elam J.D. | Founder, CEO & Acting Chairman of the Board | 973.65k | 1967 (58 années) |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer | 738.86k | 1975 (50 années) |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs | N/A | |
| Mr. Michael R. Deperro | Senior VP & Head of Corporate Development | N/A | |
| Mr. Michael Covarrubias | Senior VP & Head of Program & Portfolio Management | N/A | |
| Mr. Chris Milks | VP & Head of Finance | N/A | |
| Dr. Raj Agrawal M.D. | VP & Head of Ophthalmological Clinical Development | N/A | |
| Ms. Robyn Sweinhart | VP & Head of Quality | N/A | |
| Mr. Daron G. Evans M.B.A., M.S. | Chief Financial Officer | N/A | 1974 (51 année) |
| Ms. Erin O'Boyle | Senior VP & Head of Clinical Operations |
Informations sur l'entreprise
Adresse: United States, Redwood City. CA, 201 Redwood Shores Parkway - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.rezolutebio.com
Site web: https://www.rezolutebio.com
